Home
NewsNewsIran Health Agency Expands Fertility Treatment Services to meet rising global demand, offering advanced testing, IVF, expert consultation, and full post-treatment follow-up. The program also includes visa assistance, travel coordination, accommodation support, and multilingual guidance, ensuring international patients receive structured, end-to-end reproductive care in Iran.
A leading medical tourism facilitator in Iran, Iran Health Agency Expands Fertility Treatment options for international patients in an announcement. These services would have in them advanced evaluation, specialized consultation, and IVF treatments, along with comprehensive post-treatment follow-up.
It is worth noting that the agency coordinates care by way of assisting patients all across the treatment process, right from those initial inquiries and appointment scheduling to post-treatment communication along with the medical providers.
Due to a growing global demand when it comes to high-quality and dependable fertility care, the Iran Health Agency now provides fertility treatment options like a comprehensive range of fertility services, which includes consultation with experts, advanced testing for couples, IVF as well as other assisted reproductive technologies, and of course complete support all throughout the medical journey. These services are crafted to ensure a safe, comfortable, as well as a successful experience as far as international patients traveling to Iran are concerned, especially in the gamut of fertility treatment.
As per the spokesperson from the agency, their mission is to ensure that every step of the fertility treatment journey for international patients is clear, safe, and without any hassles. Through offering complete support right from initial consultation to post-treatment follow-up, patients are going to get the best possible opportunity to attain their family planning targets.
Iran Health Agency now offers a range of services that include the likes of -
Besides the Iran Health Agency Expands Fertility Treatment and offering medical services, the agency also rolls out assistance for visas, travel coordination, accommodation, and airport transfers, as well as 24/7 multilingual support to make sure that the patients complete their treatment journey in a very efficient way, with immense peace of mind.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
